How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

43,734 results for

Hypertension Evaluation History

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Diagnosis of chronic thromboembolic pulmonary hypertension: A Canadian Thoracic Society clinical practice guideline update

hypertension Pulmonary hypertension (PH) is a serious condition of the pulmonary blood vessels characterized by increased pulmonary arterial pressure (PAP) and is often associated with progressive right ventricular (RV) failure and a high risk of death. PH is increasingly recognized as an important cause of dyspnea and exercise limitation in many patients. As per the current World Health Organization (WHO) PH classification updated at the Sixth World Symposium on Pulmonary Hypertension held in 2018 in Nice (...) with previous pulmonary embolism. Thromb Res. 2009;124(3):256–258. 10. Gary T, Starz I, Belaj K, et al. Hyperlipidemia is associated with a higher pulmonary artery systolic pressure in patients after pul- monary embolism. Thromb Res. 2012;129(1):86–88. 11. Giuliani L, Piccinino C, D’Armini MA, et al. Prevalence of undiag- nosed chronic thromboembolic pulmonary hypertension after pul- monary embolism. Blood Coagul Fibrinolysis. 2014;25(7):649–653. 12. Gu erin L, Couturaud F, Parent F, et al. Prevalence

2019 Canadian Thoracic Society

42. ESC/ESH Management of Arterial Hypertension Full Text available with Trip Pro

hypertension3037 4.7.1 White-coat hypertension3037 4.7.2 Masked hypertension3038 4.8 Screening for the detection of hypertension3038 4.9 Confirming the diagnosis of hypertension3038 4.10 Clinical indications for out-of-office blood pressure measurements3038 4.11 Blood pressure during exercise and at high altitude3040 4.12 Central aortic pressure3040 5 Clinical evaluation and assessment of hypertension-mediated organ damage in patients with hypertension3041 5.1 Clinical evaluation3041 5.2 Medical history3041 (...) therapy3090 8.21 Perioperative management of hypertension3090 9 Managing concomitant cardiovascular disease risk3091 9.1 Statins and lipid-lowering drugs3091 9.2 Antiplatelet therapy and anticoagulant therapy3091 9.3. Glucose-lowering drugs and blood pressure3092 10 Patient follow-up3092 10.1 Follow-up of hypertensive patients3092 10.2 Follow-up of subjects with high–normal blood pressure and white-coat hypertension3092 10.3 Elevated blood pressure at control visits3093 10.4 Improvement in blood pressure

2018 European Society of Cardiology

43. Impact of Admission Systolic Blood Pressure and Antecedent Hypertension on Short-Term Outcomes After ST-Segment Elevation Myocardial Infarction: Strobe-Compliant Article. Full Text available with Trip Pro

Impact of Admission Systolic Blood Pressure and Antecedent Hypertension on Short-Term Outcomes After ST-Segment Elevation Myocardial Infarction: Strobe-Compliant Article. We evaluated the combined effect of admission systolic blood pressure (SBP) and antecedent hypertension on short-term outcomes in patients with ST-segment elevation myocardial infarction (STEMI). Data were derived from a multicenter survey of 7303 consecutive patients with STEMI. Patients were divided into 4 groups according (...) to different blood pressure status: high SBP without hypertension, high SBP with hypertension, low SBP without hypertension, and low SBP with hypertension. The primary endpoints were 7 and 30-day all-cause mortality. The prevalence of hypertension was 40.7%, and the best cutoff of admission SBP for predicting 30-day mortality was 108 mmHg by receiver-operating characteristic curve. Patients with hypertension were older, more often female, also had longer onset-to-admission time, more comorbidities

2015 Medicine

44. RIBOGENE: Optimisation of Riboflavin Status in Hypertensive Adults With a Genetic Predisposition to Elevated Blood Pressure

the maximum number of saved studies (100). Please remove one or more studies before adding more. RIBOGENE: Optimisation of Riboflavin Status in Hypertensive Adults With a Genetic Predisposition to Elevated Blood Pressure (RIBOGENE) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02463513 Recruitment Status (...) RIBOGENE: Optimisation of Riboflavin Status in Hypertensive Adults With a Genetic Predisposition to Elevated Blood Pressure RIBOGENE: Optimisation of Riboflavin Status in Hypertensive Adults With a Genetic Predisposition to Elevated Blood Pressure - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached

2015 Clinical Trials

45. Updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension Full Text available with Trip Pro

S8 online), or cardiomyopathy with elevated left ventricular end-diastolic filling pressures. AVT, acute vasoreactivity testing; ASD, atrial septal defect; CHD, congenital heart disease; iNO, inhaled nitric oxide; PAH, pulmonary arterial hypertension; PDA, patent ductus arteriosus; PH, pulmonary hypertension; PHVD, pulmonary hypertensive vascular disease; pre-OP, preoperatively; PVR, pulmonary vascular resistance; PVRi, pulmonary vascular resistance index; Qp, pulmonary blood flow; Qs, systemic (...) : , , , , , , , , Pulmonary hypertension (PH) and associated pulmonary vascular disease (PVD) are characterized by pulmonary vascular remodeling leading to elevated pulmonary arterial pressure and, over time, right ventricular (RV) dysfunction, underfilling/compression of the left ventricle, and terminal heart failure. x 1 Humbert, M, Guignabert, C, Bonnet, S et al. Pathology and pathobiology of pulmonary hypertension: State of the art and research perspectives. Eur Respir J . 2019 ; 53 , x 2 Vonk Noordegraaf, A, Chin

2019 International Society for Heart and Lung Transplantation

46. Transjugular Intrahepatic Portosystemic Stent-Shunt (TIPSS) in the management of portal hypertension

). It is aimed at teams of health professionals who refer patients to specialists for a Transjugular intrahepatic portosystemic stent-shunt (TIPSS). This patient summary aims to summarise the key recommendations. TIPSS is a non-surgical treatment for patients with liver disease and higher than normal pressures in the liver and surrounding blood vessels (known as portal hypertension), in particular the portal vein and hepatic veins. It involves a specialist (doctor) known as an interventional radiologist (...) Transjugular Intrahepatic Portosystemic Stent-Shunt (TIPSS) in the management of portal hypertension British Society of Gastroenterology Transjugular Intrahepatic Portosystemic Stent-Shunt (TIPSS) in the management of portal hypertension. Contents Guidelines development group 3 Abstract 4 Executive summary of recommendations 4 Research recommendations: 12 Patient summary 14 Introduction 17 Guideline development 17 Assessing the quality of guidelines: The AGREE II instrument 17 History of TIPSS

2019 British Society of Gastroenterology

47. Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report

Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report Therapy for Pulmonary Arterial Hypertension in Adults - CHEST Follow CHEST: Email/Username: Password: Remember me Search Terms Search within Search Share this page Volume 155, Issue 3, Pages 565–586 To read this article in full, please review your options for gaining access at the bottom of the page. Therapy for Pulmonary Arterial Hypertension in Adults Update of the CHEST Guideline (...) CORRESPONDENCE TO: David B. Badesch, MD, FCCP, University of Colorado Denver, 12401 E 17th Ave, Aurora, CO 80045 DOI: | Publication History Published online: January 17, 2019 To view the full text, please login as a subscribed user or . Click to view the full text on ScienceDirect. Figures Figure 1 Guideline algorithm for pharmacologic therapy for PAH in adults. Where multiple drug options are provided, there is no comparative effectiveness data to suggest greater benefit of one therapy over the other

2019 American College of Chest Physicians

48. Elevated blood pressure and illness beliefs: a cross-sectional study of emergency department patients in Jamaica Full Text available with Trip Pro

Elevated blood pressure and illness beliefs: a cross-sectional study of emergency department patients in Jamaica Elevated blood pressure (BP) is common among emergency department (ED) patients. While some data exist on the association between ED BP and hypertension (HTN) in the USA, little is known about this relationship in Afro-Caribbean nations. The aim of the study was to evaluate the relationship between elevated systolic BP in the ED and a previous diagnosis of HTN, accounting (...) as a whole, by HTN history and by presenting BP subgroup (with systolic BP ≥ 140 mmHg considered elevated). Data between groups were compared using chi-square and t tests, where appropriate.A total of 307 patients were included: 145 (47.2%) had a prior history of HTN, 126 (41.4%) had elevated BP, and 89 (61.4%) of those presenting with elevated blood pressure had a previous diagnosis of HTN. Those with less formal education were significantly more likely to present with elevated BP (52.1 vs. 28.8

2018 International journal of emergency medicine

49. Trial of Oral Melatonin in Elevated Blood Pressure

Sciences Information provided by (Responsible Party): Zinat Hatmi, Tehran University of Medical Sciences Study Details Study Description Go to Brief Summary: Since, lowering blood pressure (BP) in elevated blood pressure individuals represents an excellent opportunity to for primary prevention of hypertension (HTN). Therefore, it is planned to use a safe treatment option - oral melatonin supplementation - associated with lifestyle interventions according to the American college of cardiology/American (...) heart association (ACC/AHA) 2013 guideline in elevated blood pressure individuals to mitigate systolic and diastolic BP and ultimately, to prevent the development of HTN. Hypothesis: Melatonin therapy can lower the systolic and diastolic BP of elevated blood pressure individuals Melatonin can attenuate levels of circulatory biomarkers of Hs- CRP, Cholesterol, LDL-c and triglyceride Condition or disease Intervention/treatment Phase Elevated Blood Pressure Drug: Placebo oral capsule/placebo comparator

2018 Clinical Trials

50. Global Vascular Protection Therapy for Adults with Hypertension Without Compelling Indications for Specific Agents

measurement of BP], and Supplemental Table S2 [Recommended Technique for Automated Office BP]). Patient selection for intensive management is recommended and caution should be taken in certain high-risk groups (Table 4; Grade B). In 2016, a new recommendation to consider intensive BP control targeting an SBP ≤ 120 mm Hg in selected high-risk patients. This recommendation is based primarily upon the Systolic Blood Pressure Intervention Trial (SPRINT) . SPRINT was a randomized controlled trial that enrolled (...) . In selected high-risk patients who might potentially benefit from lower BP targets, several major considerations should be made before implementing an intensive treatment strategy. First, risk evaluation should be primarily informed by the inclusion criteria used in the SPRINT trial (Table 5). Second, the risks and benefits of intervention should be carefully weighed, because patients with hypertension are at risk for adverse vascular events and also for adverse treatment effects. Caution should

2018 Hypertension Canada

51. Treatment of Hypertension in Association With Ischemic Heart Disease

myocardial infarction. Systematic overview of individual data from 100,000 patients in randomized trials. Circulation 1998;97:2202-12. Gustafsson F, Kober L, Torp-Pedersen C, Hildebrandt P, for the Trandolapril Cardiac Evaluation study. Influence of a history of arterial hypertension and pretreatment blood pressure on the effect of angiotensin converting enzyme inhibition after acute myocardial infarction. J Hypertens 1998;16 (suppl 1):S65-S70. Kostis JB. The effect of enalapril on mortal and morbid (...) , Kober L, Torp-Pedersen C, Hildebrandt P for the Trandolapril Cardiac Evaluation study. Influence of a history of arterial hypertension and pretreatment blood pressure on the effect of angiotensin converting enzyme inhibition after acute myocardial infarction. J Hypertens 1998;16 (suppl 1):S65-S70. Kostis JB. The effect of enalapril on mortal and morbid events in patients with hypertension and left ventricular dysfunction. Am J Hypertens 1995;8:909-14. The Beta-Blocker Pooling Project Research Group

2018 Hypertension Canada

52. Indications for Drug Therapy for Adults With Hypertension Without Compelling Indications for Specific Agents

-linear fashion with increased BP . Further, numerous trials show antihypertensive therapy reduces relative risk of cardiovascular events by approximately 25% to 30%, irrespective of pre-treatment BP, (at least for diastolic BPs in excess of 90 mm Hg) — of course, Early trials generally enrolled patients with diastolic blood pressures in excess of 90 mm Hg and later trials enrolled patients with elevated systolic blood pressure (often greater than 160 mmHg) . Recommendations for hypertension (...) with elevated diastolic blood pressure. The Hypertension Detection and Follow-up Program (HDFP), a 5-year pragmatic randomized trial comparing an intensive antihypertensive treatment program with usual care, is a notable example. This trial reported a statistically significant 17% reduction in total mortality in the overall trial . Mortality was also reduced (5.9% with active treatment vs. 7.4% for usual care; P < 0.01) in the subgroup of 7825 patients with DBP levels between 90 and 104 mm Hg . Relative

2018 Hypertension Canada

53. Treatment of Hypertension in Association With Diabetes Mellitus

with significant elevations in blood pressure. Caution, however, should be exercised in patients in whom a substantial fall in BP is more likely to occur or is more poorly tolerated (e.g., the elderly and patients with autonomic neuropathy). Regarding systolic BP targets, two major meta-analyses have examined the relative benefits and risks of achieving lower SBP in patients with diabetes mellitus and hypertension. The Bangalore et al. meta-analysis included trials comparing achieved SBP levels of < 135 mm Hg (...) complications (e.g., retinopathy and nephropathy), as well as macrovascular complications in patients with hypertension, who have diabetes mellitus. The association between BP level (systolic and diastolic) and cardiovascular risk is continuous and graded in patients with diabetes mellitus. Treatment of hypertension appears to confer greater benefits in people with diabetes than in age-matched people with hypertension, who do not have diabetes , and the benefits of aggressive blood pressure lowering may

2018 Hypertension Canada

54. Treatment of Hypertension in Association With Heart Failure

for thiazide/thiazide-like diuretics for BP control, Grade D for loop diuretics for volume control). Beyond considerations of BP control, doses of ACE inhibitors or ARBs should be titrated to those found to be effective in trials unless adverse effects become manifest (Grade B). An ARB is recommended if ACE inhibitors are not tolerated (Grade A). A combination of hydralazine and isosorbide dinitrate is recommended if ACE inhibitors and ARBs are contraindicated or not tolerated (Grade B). For hypertensive (...) patients whose BP is not controlled, an ARB may be added to an ACE inhibitor and other antihypertensive drug treatment (Grade A). Careful monitoring should be used if combining an ACE inhibitor and an ARB because of potential adverse effects such as hypotension, hyperkalemia, and worsening renal function (Grade C). Additional therapies might also include dihydropyridine CCBs (Grade C). An Angiotensin Receptor-Neprilysin Inhibitor combination should be used in place of an ACE inhibitor or ARB

2018 Hypertension Canada

55. Prevention & Treatment of Hypertension - Health Behaviour Management

controlled trials of weight loss demonstrate that a reduction in weight is associated with a reduction in blood pressure in overweight hypertensive patients . For overweight patients, efficacy of weight loss in reducing BP is similar to that of single antihypertensive drug therapy . 3. Weight loss strategies should use a multidisciplinary approach that includes dietary education, increased physical activity, and behavioural intervention (Grade B). Multidisciplinary approaches to weight loss appear (...) , Robinette D, Fabsitz R. Concordance, discordance and prevalence of hypertension in World War II male veteran twins. J Hypertens 1994;12:323-8. Fournier AM, Hoenig LJ, Sosenko JM. The degree of blood pressure evaluation and end organ damage with severe hypertension: a case-controlled study. Am J Med Sci 1993;306:367-70. Stamler R, Stamler J, Grimm R, Gosch FC, Elmer P, Dyer A, et al. Nutritional therapy for high blood pressure. Final report of a four-year randomized controlled trial — the Hypertension

2018 Hypertension Canada

56. Diagnosis & Assessment of Hypertension - Diagnosis

of progression to overt hypertension; and (b) a worse prognosis than patients with optimal blood pressure levels. Therefore, although antihypertensive therapy is not recommended, close surveillance in the form of annual blood pressure checks is recommended. 3. If the visit 1 mean OBPM or AOBP is high (see thresholds outlined in ), a history and physical examination should be performed and, if clinically indicated, diagnostic tests to search for target organ damage (Supplemental ) and associated (...) to 2.3) and women (hazard ratio 1.8; 95% CI 1.0 to 3.1) with high normal BP than in subjects with BP levels lower than 120/80 mm Hg . Those older than 65 years of age with high normal BP levels had the highest risk of progression to hypertension and development of cardiovascular disease. In this group, the crude incidence rate of cardiovascular events per 1000 patient years was 20 in women and 28 in men . These data indicate that patients with high normal blood pressure have (a) a higher risk

2018 Hypertension Canada

57. China Antihypertensive Trial in Acute Ischemic Stroke II

Association class III and IV) or left ventricular ejection fraction <35% Myocardial infarction or unstable angina within past 3 months History of atrial fibrillation. History of aortic dissection History of all-cause dementia Difficult-to-control hypertension (systolic blood pressure ≥170 mmHg despite use of ≥4 antihypertensive medications for ≥6 months) Acute renal failure or dialysis or estimated glomerular filtration rate (eGFR) <20 ml/min/1.73 m2 Any clinical conditions judged by the clinic team (...) pressure (BP) between 140-200 mmHg at randomization. Patients with extracranial or intracranial artery stenosis (≥70%) in both sides or the affected side, NIH Stroke Scale score of ≥21, Glasgow Coma Scale score <8, preceding moderate or severe dependency (modified Rankin scale score 3-5), revascularization, intravenous thrombolytic therapy or mechanical thrombectomy will be excluded. All eligible patients will discontinue their home antihypertensive medications. Patients admitted within 24 hours

2018 Clinical Trials

58. Efficacy of Fixed-doses of Antihypertensive and Statin Drugs

of Antihypertensive and Statin Drugs The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03401580 Recruitment Status : Not yet recruiting First Posted : January 17, 2018 Last Update Posted : January 17, 2018 See Sponsor: EMS Information (...) provided by (Responsible Party): EMS Study Details Study Description Go to Brief Summary: The purpose of this study is to evaluate the efficacy of different fixed-dose combination of Viena II in treatment of hypertension and dyslipidemia. Condition or disease Intervention/treatment Phase Hypertension Dyslipidemia Drug: Viena II 160/10 Drug: Viena II 190/10 Drug: Viena II 160/12 Drug: Viena II 190/12 Phase 2 Detailed Description: Fase II, national, multicenter, randomized, double-blind. Maximal duration

2018 Clinical Trials

59. Recommendations on screening for high blood pressure in Canadian adults

and Evaluation) 23 criteria. The quality of evidence was determined based on the CTFPHC’s con- fidence in their estimates and the rigour of their guide- line development process. 3. For people who are found to have an elevated blood pressure measurement during screening, the CHEP crite- ria for assessment and diagnosis of hypertension should be applied to determine whether the patients meet diag- nostic criteria for hypertension 6 : The 2012 CHEP rec- ommendations for assessment and diagnosis of high blood (...) routinely, ideally at each health care encounter, but no less than once annually BPblood pressure, CHEP—Canadian Hypertension Education Program, CTFPHC—Canadian Task Force on Preventive Health Care, DBP—diastolic blood pressure, SBP—systolic blood pressure, USPSTF—US Preventive Services Task Force. *The interval comes from the 2000 sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, 17 which recommends screening every 2 y with BP

2013 CPG Infobase

60. Study to Evaluate the Effect of Celecoxib on the Efficacy and Safety of Amlodipine in Subjects With Hypertension Requiring Antihypertensive Therapy

table for additonal information Responsible Party: Kitov Pharma Ltd ClinicalTrials.gov Identifier: Other Study ID Numbers: KIT-302-03-01 2013-005381-19 ( EudraCT Number ) First Posted: June 24, 2014 Results First Posted: October 3, 2017 Last Update Posted: October 10, 2018 Last Verified: September 2018 Keywords provided by Kitov Pharma Ltd: High blood pressure Systolic blood pressure Diastolic blood pressure Antihypertensive Additional relevant MeSH terms: Layout table for MeSH terms Hypertension (...) Study to Evaluate the Effect of Celecoxib on the Efficacy and Safety of Amlodipine in Subjects With Hypertension Requiring Antihypertensive Therapy Study to Evaluate the Effect of Celecoxib on the Efficacy and Safety of Amlodipine in Subjects With Hypertension Requiring Antihypertensive Therapy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies

2014 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>